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Abstract: The clinical utility of a biomarker depends on its ability to identify high-risk individuals to optimally manage 
the patient. A new biomarker would be of clinical value if it is accurate and reliable, provides good sensitivity and speciﬁ  c-
ity, and is available for widespread application. Data are accumulating on the potential clinical utility of integrating imaging 
technologies and circulating biomarkers for the identiﬁ  cation of vulnerable (high-risk) cardiovascular patients. A multi-
biomarker strategy consisting of markers of inﬂ  ammation, hemostasis and thrombosis, proteolysis and oxidative stress, 
combined with new imaging modalities (optical coherence tomography, virtual histology plus IVUS, PET) can increase our 
ability to identify such thombosis-prone patients. In an ideal scenario, cardiovascular biomarkers and imaging combined 
will provide a better diagnostic tool to identify high-risk individuals and also more efﬁ  cient methods for effective therapies 
to reduce such cardiovascular risk. However, additional studies are required in order to show that this approach can con-
tribute to improved diagnostic and therapeutic of atherosclerotic disease.
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Introduction
Atherosclerotic disease and its thrombotic complications (atherothrombosis) remain the leading cause 
of mortality and morbidity in Western society. The mortality associated with atherosclerotic disease is 
related to the acute coronary syndromes (ACS), including acute myocardial infarction, unstable angina 
pectoris and sudden cardiac death. There is substantial clinical, experimental and postmortem evidence 
demonstrating the role of acute thrombosis on disrupted atherosclerotic plaques in the onset of ACS. 
Atherosclerotic plaque composition, rather than stenotic severity, appears to be central in determining 
risk of both plaque rupture and subsequent thrombogenicity. Inﬂ  ammation plays a central role throughout 
the entire disease progression, and it lies at the root of atherosclerosis and its complications (1–3). 
Plaques within the coronary circulation become “high-risk” (vulnerable plaque) in response to a wide 
array of local and systemic inﬂ  uences/atherosclerotic risk factors. Thrombus formation in association 
with these lesions may be accelerated or ampliﬁ  ed under the same inﬂ  uences (vulnerable blood). Simi-
larly, at risk myocardium that is prone to rhythm disturbances or subject to ischemic ﬂ  ow is likely to 
experience dysfunction (vulnerable myocardium). Therefore, a combination of risk factors contributes 
to a vulnerable plaque composition, prothrombotic milieu, and susceptible heart, conditions that strongly 
favor the clinical manifestations of ACS (4). We are currently limited in our ability to identify accurately 
patients at risk of ACS. However, new imaging modalities in combination with the development of new 
biomarkers (bioimaging) may improve our understanding and management of patients at risk of coro-
nary artery disease in the new millennium.
Atherosclerotic Plaque Imaging
There is growing evidence that different types of vulnerable plaques exist that have different functional and 
biological features. Plaques may have similar structural features and morphologic assessment, but may 
differ in their biology, their activity, and thus their likelihood of advancing toward clinical complications.
In the past, invasive coronary angiography has been the only diagnostic procedure for identifying coro-
nary atherosclerosis. Angiography provides purely morphologic information about vessel lumen diameter. 
However, various clinical observations in recent years have emphasized the need for more detailed analysis 
of atherosclerotic plaques. Several methods are available that provide detailed information about vessel 
Biomarker Insights 2006:1 165–173166
Páramo et al
wall and plaque morphology (Table 1). The goal of 
these techniques is to identify vascular remodeling 
and describe plaque with regard to speciﬁ  c morpho-
logic criteria concerning vulnerability (5).
Intravascular ultrasound (IVUS) is a catheter-
based technology that allows for assessment of vessel 
wall thickness and structure. Coronary angioscopy 
also allows to visualize the vessel lumen. But, 
because of their invasive nature, these techniques 
are not suitable as screening methods. More recently, 
optical coherence tomography (OCT) and virtual 
histology/IVUS have been introduced as other inva-
sive techniques that provide images of vessel wall 
morphology and plaque characteristics. In contrast 
to these invasive approaches, noninvasive technolo-
gies such as electron beam computed tomography 
(EBCT) allow for high resolution assessment of 
coronary artery luminal morphology. This method 
is characterized by a high negative predictive value 
for exclusion of coronary disease (6–9). Some studies 
also suggest a potential value for determination of 
plaque composition and vulnerability (10). Finally, 
a variety of approaches at the molecular level (e.g. 
positron emission tomography, Technetium99m-
labeled annexin V), targeting plaque inﬂ  ammation, 
apoptosis, smooth muscle cell proliferation, extracel-
lular matrix (ECM) activation, or platelet binding, 
have been recently introduced (11).
Biomarkers of “vulnerable blood”
Biomarkers are generally considered to be systemic 
measurements of molecules, proteins, or enzymes 
Table 1. Atherosclerosis imaging technologies.
Technique Information  Advantages Limitations 
Coronary angiography  Coronary change score  Common procedure  Invasive
  Change in percent stenosis  Clinical experience  Provides lumen size only
Carotid IMT  Change in mean IMT  Noninvasive, availability   Technically demanding
    and cost  Noncoronary assessment
EBCT  Change in Agatson   Noninvasive  Limited reproducibility 
  score    Not commonly used in 
     clinical  trials
Brachial artery  Flow-mediated  Noninvasive, availability  Need for standardized
ultrasound dilatation  and  cost  protocols 
IVUS  Absolute change in  Direct imaging of the  Invasive  
  plaque volume  disease  Plaque composition 
  Percent change in  Standardized protocols   difﬁ  cult to assess
   plaque and atheroma   Clinical experience  Assess anatomy, not
 volume    function
Magnetic resonance  Change in mean vessel  Noninvasive   No validation with
  wall area  Plaque characterization  clinical events
 Vessel  calciﬁ  cation  possible
OCT  Unstable/vulnerable  High resolution, high  Invasive 
  plaque  data acquisition rate  Attenuation by blood
  Plaque composition  Can be combined with  Limited penetration in
   adjuvant  optical  tissue
   techniques  No  validation  with
     clinical  events
Virtual histology/IVUS  Plaque morphology   High predictive accuracy  Invasive 
 (lipid  vs  ﬁ  brous)  Ability for detection of  Unable to differentiate 
  Vulnerable plaque  vulnerable plaques  thrombus 
     No  validation  with
     clinical  events
OCT: Optical coherence tomography; IVUS: Intravascular ultrasound; EBCT: electron beam computed tomography; 
IMT: intima-media thickness.
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that provide independent diagnostic or prognostic 
value by reﬂ  ecting an underlying disease state or 
condition. The clinical utility of a biomarker 
depends on its ability to identify high-risk patients, 
be accurate and reliable, and provide good sensi-
tivity, speciﬁ  city and predictive value. Clinical 
application further requires the demonstration that 
evaluation of the biomarker is not only predictive 
of disease, but also adds predictive value to tradi-
tional risk factors and global vascular risk assess-
ment, such as the Framingham score. In the case 
of coronary artery disease, the marker must reﬂ  ect 
the underlying biology of the vessel wall, quanti-
fying cardiovascular specific inflammation, 
thereby predicting the risk of recurrent athero-
thrombosis and its sequelae (12, 13). Historically, 
cholesterol and, in particular, LDL-cholesterol, has 
been considered the prototypical risk factor for 
coronary artery disease. However, lipoproteins 
alone do not explain all the coronary artery disease 
risk; one-half of all heart attacks and strokes occur 
among individuals without hypercholesterolemia, 
and one-ﬁ  fth of all cardiovascular events occur in 
the absence of any of the major risk factors. Addi-
tional and new biomarkers are therefore needed to 
diagnose and prognosticate coronary artery disease 
more precisely (Table 2) (14).
Cytokines
Cytokines are pleiotropic proteins that regulate 
leukocyte activity. Interleukin-6, monocyte 
chemoattractant protein-1(MCP-1) and TNF-α 
have shown promise in the prediction of coronary 
heart disease (15). Patients with ACS have 
increased circulating levels of IL-6 compared with 
those patients with stable angina (16). Measure-
ment of MCP-1 in the coronary sinus blood of 
patients with unstable angina demonstrate an 
Table 2. Bioimaging for identifying the vulnerable (high-risk) patient.
Arterial vulnerability  Blood vulnerability  Myocardial vulnerability
1) Structural markers 1)  Hypercoagulable 1)  Structural markers
    - Carotid IMT      - Fibrinogen      - LVH
    - Coronary artery calcium      - D-dimer      - LV dysfunction
      - Prothrombin fragment 1+2
2) Functional markers 2)  Decreased ﬁ  brinolysis 2)  Functional markers
    - Blood pressure    - t-PA      - Exercise stress test
    - Endothelial dysfunction      - PAI-1      - PET
   -  Arterial  stiffness      
   -  Ankle-brachial  index       
    - Urine albumin excretion                 
3) Serological markers 3)  Increased coagulation factors 3)  Serological markers
    - Abnormal lipid proﬁ  le    - von Willebrand factor    - Troponins
      -  Oxidized-LDL        -  Pro-BNP
      -  LP-PLA2     -  H-FABP
   -  Inﬂ  ammation
- hs-CRP
- Interleukins
- SAA
- MPO
- sCD40L
    - Oxidative stress
   -  Homocysteine
    - Natriuretic peptides
    - MMPS: -9, -10
   -  TIMPS
                                          H-FABP: Heart-fatty acid binding protein; IMT: intima-media thickness; LP-PlA2: lipoprotein-associated phospholipase A2; LV: left ventricle; 
LVH: LV hypertrophy; MMPs: metalloproteinases; MPO: myeloperoxidase; SAA: serum amyloid A; sCD40L: soluble CD40 ligand; PAI-1: 
Plasminogen activator inhibitor; PET: positron emission tomography; Pro-BNP: B-type natriuretic peptide; TIMPs: tissue inhibitors of MMPs; 
t-PA: tissue plasminogen activator. 
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association with the extent of coronary atheroscle-
rosis as assessed by angiography (17). In the 
CARE trial in patients with a recent myocardial 
infarction (MI), those who experienced a recurrent 
MI or cardiac death had higher TNF-α levels than 
matched controls (18). However, as the number 
of cytokines implicated in ACS increases, it will 
become important to determine whether they 
provide independent prognostic information apart 
from more established inﬂ  ammatory biomarkers 
such as C-reactive protein.
C-Reactive protein (CRP) and other 
acute-phase reactants
Elevated CRP has been associated with undiag-
nosed peripheral, coronary, and cerebral artery 
disease; it differentiates patients with unstable 
versus stable angina; predicts future MI, stroke and 
sudden cardiac death in patients with coronary 
artery disease; correlates with MI; and predicts the 
presence, degree, and symptomatology of carotid 
stenosis, as well as early morbidity and late 
mortality following coronary artery bypass 
grafting, and late restenosis following percuta-
neous cardiac interventions. A major advantage of 
CRP over the other inﬂ  ammatory biomarkers is 
evidence that independently adds predictive power 
to both lipid screening and the Framingham risk 
score (19–21). Furthermore, a precise standardised, 
commercially available assay designed for cardio-
vascular risk assessment is widely available, 
complete with accepted normal ranges and 
screening guidelines from the American Heart 
Association and the Center for Disease Control 
(22). Beyond CRP’s ability to predict risk for both 
primary and secondary prevention of cardiovas-
cular disease, interest has increased with the recog-
nition that statins lower CRP in a manner largely 
independent of LDL-C reduction (23, 24).
In addition to its function as a component of the 
generalized hepatic response to acute inﬂ  amma-
tion, CRP also appears to be produced locally in 
atherosclerotic plaques by resident macrophages 
and vascular smooth muscle cells, and may be 
involved in several important steps in plaque 
genesis, progression and rupture. CRP upregulates 
endothelial cell permeability, promotes endothelial 
adhesion, is present in subintimal plaque, ﬁ  xes 
complement, recruits monocytes and macrophages 
to foci of endovascular inﬂ  ammation, and stimu-
lates local thrombogenesis. CRP may also be 
involved in foam cell generation, as it binds 
oxidized LDL with high afﬁ  nity, and the resultant 
CRP-LDL aggregates are taken up by macrophages 
(25, 26). A novel ﬁ  nding recently reported by our 
group is that CRP induces endothelial expression 
of metalloproteinases (MMPs) capable of degrading 
the extracellular matrix. CRP increased the expres-
sion of MMP-1 (collagenase) and MMP-10 
(stromelysin-2) by human endothelial cells via 
kinase pathways. In addition, subjects with CRP 
values >3mg/L had increased plasma MMP-1 and –10. 
Finally, CRP and MMP-10 colocalized within the 
endothelial layer and macrophage-rich areas in 
advanced atherosclerotic plaques. Our results show 
increased local and systemic CRP-related MMP 
activation, thus providing a link between inﬂ  am-
mation and plaque vulnerability (27). These ﬁ  nd-
ings suggest that CRP may directly mediate 
vascular tissue injury through pro-inﬂ  ammatory, 
pro-thrombotic and proteolytic actions.
Fibrinogen may increase cardiovascular risk 
because of its role in ﬁ  brin formation, platelet 
aggregation and plasma viscosity, and is also an 
acute-phase reactant that is elevated in inﬂ  amma-
tory states. Levels of ﬁ  brinogen may also be useful 
in the identiﬁ  cation of cardiovascular risk patients 
(28). The role of other acute-phase reactants, such 
as serum amyloid A, in the prediction of coronary 
risk has not been established.
Biomarkers of endothelial 
cell activation
Plasma derived soluble forms of the immuno-
globulin family members intercellular adhesion 
molecule-1 (sICAM-1) and vascular cell adhesion 
molecule-1 (sVCAM-1) have been examined as 
possible biomarkers in ACS (29). On the basis of 
studies in the acute setting it does not appear that 
sICAM is useful in risk stratiﬁ  cation of patients 
with ACS (30). In a prospective study of patients 
with non-ST elevation MI (NSTEMI), sVCAM 
were signiﬁ  cantly higher at presentation in patients 
who had a major adverse cardiovascular events at 
6 months. However, more prospective studies are 
required before sVCAM can be validated as a 
marker of coronary risk. The major utility of E-
selectin and other markers of endothelial cell 
activation may be in predicting risk of developing 
coronary artery disease in patients with stable 
lesions (31). In patients with ACS, von Willebrand 
factor (vWF) levels are raised at admission, which 
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may reﬂ  ect endothelial dysfunction/damage. vWF 
is an independent predictor of adverse outcomes 
in ACS, and also a biomarker of subclinical athero-
sclerosis, although clinical implications for an 
individual patient remain unclear (32–34). 
Markers of oxidative stress
Oxidative stress leading to modiﬁ  cation of LDL is 
an important mechanism of atherogenesis and 
plaque destabilization. Recent results suggest that 
markers of oxidative stress may have prognostic 
signiﬁ  cance in ACS (35). 
Myeloperoxidase (MPO) is produced by 
neutrophils and monocytes at sites of inﬂ  amma-
tion. MPO can generate several reactive, oxida-
tively modified intermediates able to induce 
oxidative damage to cells and tissues. Accumu-
lating evidence suggests that MPO may play a 
role in plaque vulnerability. In a prospective 
study, patients with ACS and elevated MPO levels 
had a statistically signiﬁ  cant increase in the risk 
of death or MI during the ﬁ  rst 72 hours, indepen-
dently of troponin or CRP, suggesting that MPO 
provides independent prognostic information 
distinct from other established biomarkers. 
Advanced human atherosclerotic plaques from 
patients with sudden cardiac death, strongly 
expressed MPO at sites of rupture. The most 
important use of MPO may be early risk stratiﬁ  -
cation of patients with NSTEMI (36).
Oxidized-LDL (Ox-LDL) is generated during 
lipid peroxidation, resulting in generation of reac-
tive species that modify the lipid components of 
LDL. Ox-LDL leads to foam cell formation and 
elaboration of pro-inﬂ  ammatory cytokines that 
promote endothelial dysfunction. Currently three 
major Ox-LDL plasma ELISAs based on murine 
monoclonal antibodies have been developed. 
Circulating levels of Ox-LDL have been associated 
with the presence of coronary artery disease in 
patients undergoing elective angiography; simi-
larly elevated Ox-LDL levels are signiﬁ  cantly 
higher in patients with ACS, ﬁ  nally, some but not 
all prospective studies have shown higher Ox-LDL 
levels in patients subsequent development of 
cardiac death, non-fatal MI, and unstable angina. 
Therefore, Ox-LDL is an attractive biomarker, as 
it may provide a link between lipoprotein disorders 
and inﬂ  ammation (37, 38).
Lipoprotein-associated phospholipase A2 
(Lp-PLA2) is a calcium-independent serine lipase 
that is associated with LDL in human plasma and 
serum. It is produced by macrophages and its 
expression is increased in atherosclerotic lesions 
(39, 40). A recent analysis of patients from the 
GRACE study found that elevated LP-PLA2 
activity was associated with a 3-fold increased risk 
of death or recurrent myocardial infarction, inde-
pendently of other established risk markers (41).
Several prospective epidemiological studies 
have reported that LP-PLA2 is a predictor of coro-
nary artery disease, although controversy persists 
as to its independence from LDL-C. In the most 
recent, in coronary heart disease patients who were 
followed for 4 years, increased concentration of 
this phospholipase predicted future cardiovascular 
events (HR 2.65, 95%CI 1.47–4.76), independently 
of a variety of potential risk factors, including 
markers of inﬂ  ammation, renal dysfunction and 
hemodynamic stress (42).
The NADPH oxidase constitutes the main 
source of superoxide in phagocytic and vascular 
cells. A recent study in a small series found 
increased circulating NADPH oxidase activity 
associated with carotid IMT, suggesting a relation-
ship between phagocytic NADPH oxidative stress 
and the development of atherosclerosis (43).
Proteolysis/ﬁ  brinolysis markers
Matrix metalloproteinases MMPs are zinc-depen-
dent endopeptidases with collagenase and/or gela-
tinase activity. Degradation of collagen ﬁ  brous cap 
may predispose atheromas to rupture. MMPs are 
highly expressed in atherosclerotic plaques, in 
particular in the shoulder regions. Whereas few 
data exist on the association between MMPs during 
ACS and cardiovascular outcomes, MMP-9 (gela-
tinase-B) levels are signiﬁ  cantly increased in the 
coronary circulation in patients with acute MI and 
unstable angina (44). Circulating MMP-9 levels 
are also increased in type 2 diabetes patients with 
coronary artery disease, and elevated serum MMP-
9 concentrations, associated with decreased 
inhibitor levels (TIMP-1), have been linked to 
premature coronary atherosclerosis (45–48). 
Recently, we demonstrated that MMP-10 (strome-
lysin-2) is associated with inflammation and 
subclinical atherosclerosis, and is also present in 
atherosclerotic lesions (27). 
Pregnancy-associated plasma protein A (PAPP-
A) was originally described as e peptide speciﬁ  -
cally elevated in pregnancy. Ruptured plaques have 
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demonstrated PAPP-A expression in their shoulder. 
Some studies suggest that this peptidase may have 
diagnostic utility in identifying patients with ACS 
and without troponin elevation (49,50).
Despite some controversial reports regarding 
whether MMPs inhibition may have some delete-
rious effect, recent experimental studies demon-
strate suppression of atherosclerotic plaque 
progression and instability by tissue inhibitors of 
MMPs (TIMPs), possibly through modulation of 
macrophage migration and apoptosis (51).
Fibrinolysis Tissue plasminogen activator (t-PA) 
is a key component of the cardiovascular ﬁ  brino-
lytic system. In baseline conditions, t-PA is consti-
tutively released from endothelial cells. Upon 
appropriate stimulation, substantial amounts of t-PA 
can be rapidly released resulting in a marked 
increase in ﬁ  brinolysis. The activity of t-PA in 
plasma is regulated by speciﬁ  c inhibitors. Of these, 
plasminogen activator inhibitor-1 (PAI-1) is consid-
ered to be the main inhibitor of t-PA in the vascular 
compartments, Additionally, α2-antiplasmin 
inhibits plasmin (the main proteolytic enzyme), 
thereby counteracting overhelming systemic ﬁ  bri-
nolytic activity (52). There has been growing 
interest in the relationship of impaired ﬁ  brinolysis 
and coronary heart disease and stroke. Meta-anal-
ysis have shown that increased circulating levels 
of t-PA and PAI-1 are associated with cardiovas-
cular risk. However, these associations were modest 
after adjustment for confounding established risk 
factors, and do not add signiﬁ  cantly to the predictive 
value of current clinical risk scores (53).
Biomarkers of platelet activation
CD40L, a member of the TNF family, is expressed 
by all the major cellular players in atherosclerosis, 
namely, activated T lymphocytes, EC, SMC, and 
macrophages. Studies examining circulating 
levels of soluble CD40L (sCD40L), which is 
primarily derived from activated platelets, have 
found elevated levels in patients with unstable 
angina and predicted the risk of future cardiovas-
cular events in women. A recent study examining 
sCD40L in ACS found higher levels associated 
with increased risk of death or non-fatal MI, a 
risk that was signiﬁ  cantly reduced with the glyco-
protein IIb/IIIa inhibitor abciximab (54–56). 
However, a recent study failed to show an 
association between sCD40L and subclinical 
atherosclerosis (57). 
Genetic markers
The recent completion of the Human Genome 
Project has provided a great opportunity to identify 
high-risk patients through the use of technologies 
that integrate the entire genome. Assessment of 
genetic markers might predict risk of plaque insta-
bility or response to current therapies. For example, 
analysis of 112 polymorphisms in 2819 patients 
with ACS identiﬁ  ed 3 genes (connexin 37, PAI-1 
and stromelysin 1) associated with increased risk 
of MI (58). Another study examining 62 candidate 
genes in premature MI identiﬁ  ed variants in 3 
members of the thrombospondin gene family as 
risk markers (59). Current data also provide 
evidence for the role of MMP-3 polymorphism in 
plaque destabilization (60). Finally, polymor-
phisms in specific chemokine receptors were 
associated with serum MCP-1 levels and myocar-
dial infarction in the Framingham study (61). 
Multi-marker Approach to Acute 
Coronary Syndromes
Advances in the understanding of the pathogen-
esis of acute coronary syndromes have stimu-
lated development of novel biomarkers, and 
expanded their role in the different spectra of 
their underlying pathophysiology. This multi-
marker strategy consists of an array of biomarkers 
assessing myocardial necrosis, plaque destabi-
lization, myocardial stress, myocardial ischemia 
and inﬂ  ammatory processes (62) (Figure 1). 
Those with potential clinical application include 
troponin T, for detection of minor myocardial 
damage associated with vulnerable plaque and 
thrombus, heart-type fatty acid binding protein 
(H-FABP) for earlier detection of myocardial 
damage (63), N-terminal pro-BNP for earlier 
risk stratiﬁ  cation in cardiac emergency, and 
sCD40L for earlier identiﬁ  cation of plaque desta-
bilization with platelet activation (64).
Integrating Soluble Biomarkers 
and Imaging Technologies in the 
Identiﬁ  cation of the “vulnerable 
patient”: Bioimaging
Given the complex pathophysiology of cardiovas-
cular disease, it is unlikely that any single 
biomarker will prove able to provide a universal 
surrogate of atherosclerosis. New imaging tech-
nology may be limited by technical difﬁ  culty, 
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availability and cost. Soluble biomarkers may offer 
the advantage of availability and lower cost, but 
they may not prove as sensitive as imaging modal-
ities in the detection or assessment of disease (65). 
Table 3 provides a list of molecules that may serve 
as candidates for non-invasively identiﬁ  cation of 
high-risk atherosclerotic plaques in combination 
with imaging technologies (66, 67), It should be 
noticed, as shown in the IBIS trial (9), that weak 
correlations between circulating biomarkers and 
quantiﬁ  able imaging parameters are likely to be 
found.
Table 3. Panel of biomarkers potentially associated with vascular imaging.
Biomarker  Vascular imaging
Endothelial integrins (ICAM-1, VCAM-1, P-selectin, E-selectin)
Ox-LDL  MRI
MMP-2 and -9 
VCAM-1, ICAM-1, E-selectin,
CRP  
IL-6  IVUS
LP-PlA2 
IL6, IL-10, 
Ox-LDL
MCP-1 
MMP-10  Carotid IMT
CRP
Fibrinogen
NADPH-oxidase 
Figure 1. Multi-marker approach to atherothrombosis.
Inflammation
sICAM
sVCAM
IL-1 and -6
TNF-α
MCP-1
MPO
LP-PLA2
Proteolysis
MMP-1,-2,-9,-10
PAPP-A
Thrombosis
sCD40L
sP-Selectin
PAI-1
thrombus thrombus
lipid-rich
necrotic core
lipid-rich
necrotic core
smooth muscle cells smooth muscle cells
LDL
platelet
monocyte
vessel
lumen
erythrocyte
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In summary, with a multimarker approach 
combining emerging and new biomarkers with 
imaging technology, better risk profiles may 
emerge to provide prognostic information. A panel 
of inflammatory hemodynamic and vascular 
damage biomarkers, as part of a multimarker 
strategy (Figure 1), may help us to understand the 
pathophysiological mechanism underlying ACS 
and contribute to the development of new thera-
peutics in atherosclerosis (68,69).
Hopefully, bioimaging, by integrating 
biomarkers and imaging studies, offers a new 
opportunity to identify not only “vulnerable 
plaques” but also “vulnerable patients” for targeted 
therapeutic interventions.
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